GeneSight, a Mason-based company specializing in mental health medication, expanded its wellness services in the community.

盐湖城 - 专门从事基因测试和精准医疗的Myriad Genetics, Inc. (NASDAQ: MYGN)宣布对联合健康最近的政策更新表示不同意。该保险公司计划从2025年1月1日起，在其商业和个人交换福利计划下限制多基因组药物基因组学测试的覆盖范围，包括Myriad的GeneSight测试。 这一政策变更于周五传达给Myriad，公司对此表示惊讶和失望。Myriad的总裁兼首席执行官Pau ...

Myriad Genetics Inc (MYGN) reports robust revenue growth and strategic initiatives despite facing policy changes impacting ...

Myriad Genetics (NASDAQ:MYGN) is down ~20% in Friday trading following reports that UnitedHealth Group (UNH) will no longer ...

周一，TD Cowen维持Myriad Genetics (NASDAQ:MYGN)股票的持有评级，目标价保持在$30.00不变。这一决定是在联合健康(UNH)最近更改药物基因检测政策之后做出的。 具体而言，UNH更新了其指南，排除了对多基因检测的覆盖，包括Myriad Genetics的GeneSight产品，该产品用于指导抗抑郁药物治疗。在这一公告之后，Myriad Genetics的股价下跌 ...

Investigation Details On October 31, 2024, it was revealed that UnitedHealth Group (“UnitedHealth”) would no longer cover GeneSight, Myriad’s genetic test to help determine which mental health ...

Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.

UnitedHealth (UNH) on Friday disclosed that it would stop covering multi-panel pharmacogenetic tests, including Myriad’s (MYGN) ...

The insurer plans to restrict coverage for multi-gene panel pharmacogenetic tests, including Myriad's GeneSight, under its commercial and individual exchange benefit plans starting January 1 ...

The company is scheduled to hold its third quarter 2024 earnings conference call after the market closes on Thursday November 7, 2024, and intends to provide additional information regarding its ...

Notes from several investment houses indicate that the insurance giant will no longer cover genetic tests for behavioral health, which includes Myriad's GeneSight, beginning Jan. 1, 2025.